Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and another hormone, may provide a significant step forward for obesity management . Preliminary patient trials have indicated impressive decreases in body mass , potentially exceeding current weight-loss medications . Nevertheless , more assessment is needed to thoroughl